Search results
Results from the WOW.Com Content Network
A transcriptional activator is a protein (transcription factor) that increases transcription of a gene or set of genes. [1] Activators are considered to have positive control over gene expression, as they function to promote gene transcription and, in some cases, are required for the transcription of genes to occur.
PGC-1α leads to calcineurin activation. [22] Akt and calcineurin are both activators of NF-kappa-B (p65). [23] [24] Through their activation, PGC-1α seems to activate NF-kappa-B. Increased activity of NF-kappa-B in muscle has recently been demonstrated following induction of PGC-1α. [25] The finding seems to be controversial.
The dCas9 activation system allows a desired gene or multiple genes in the same cell to be expressed. It is possible to study genes involved in a certain process using a genome wide screen that involves activating expression of genes. Examining which sgRNAs yield a phenotype suggests which genes are involved in a specific pathway.
It is required for the successful transcription of nearly all class II gene promoters in yeast. [7] It works in the same manner in mammals. The mediator functions as a coactivator and binds to the C-terminal domain of RNA polymerase II holoenzyme , acting as a bridge between this enzyme and transcription factors .
Hepatocyte growth factor activator is a protein that in humans is encoded by the HGFAC gene. [5] [6] [7]The protein encoded by this gene, belongs to peptidase family S1. It is first synthesized as an inactive single-chain precursor before being activated to a heterodimeric form by endoproteolytic processing.
The AOL.com video experience serves up the best video content from AOL and around the web, curating informative and entertaining snackable videos.
Tetracycline-controlled transcriptional activation is a method of inducible gene expression where transcription is reversibly turned on or off in the presence of the antibiotic tetracycline or one of its derivatives (e.g. doxycycline).
The PAX3-MAML3 fusion juxtaposes the N-terminal PAX3 DNA binding domain with the C-terminal MAML3 transactivation domain to create another potent activator of target genes with PAX3 binding sites. Of note, PAX3 is rearranged without MAML3 involvement in a smaller subset of BSNS cases, and some of these variant cases contain a PAX3-NCOA1 or PAX3 ...